These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12445247)

  • 1. Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study.
    Gordinier ME; Kudelka AP; Kavanagh JJ; Wharton JT; Freedman RS
    Int J Gynecol Cancer; 2002; 12(6):710-4. PubMed ID: 12445247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
    Papadimitriou CA; Moulopoulos LA; Vlahos G; Voulgaris Z; Kiosses E; Georgoulias N; Gika D; Diakomanolis E; Michalas S; Dimopoulos MA
    Cancer; 2000 Oct; 89(7):1547-54. PubMed ID: 11013370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
    Gebbia V; Di Marco P; Borsellino N; Gebbia N; Valerio MR; Fallica G; Tirrito ML; Valenza R; Citarrella P; Benedetti Panici P
    Anticancer Drugs; 2003 Jun; 14(5):359-64. PubMed ID: 12782942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
    Papadimitriou CA; Kouroussis C; Moulopoulos LA; Vlahos G; Rodolakis A; Kiamouris C; Diakomanolis E; Gika D; Michalas S; Dimopoulos MA
    Cancer; 2001 Oct; 92(7):1856-63. PubMed ID: 11745258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
    Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
    Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
    Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
    Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
    Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study.
    Zamagni C; Martoni A; Cacciari N; Gentile A; Pannuti F
    Am J Clin Oncol; 1998 Oct; 21(5):491-7. PubMed ID: 9781607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study.
    Bauknecht T; Hefti A; Morack G; Villena-Heinsen C; Wallwiener D; Elling D; Minckwitz GV; Mansouri K; Blatter J; Breitbach GP
    Int J Gynecol Cancer; 2003; 13(2):130-7. PubMed ID: 12657112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
    Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
    Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
    Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.